Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2800
- Registration Number
- NCT05968599
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 26
- Registration Number
- NCT05751941
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT05733351
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT05705700
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 30
- Registration Number
- NCT05593497
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
🇺🇸VA Portland Health Care System, Portland, OR, Portland, Oregon, United States
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 382
- Registration Number
- NCT05551117
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇧🇪Centre Hospitalier Universitaire (CHU) - Universite Catholique de Louvain (UCL) - Namur - Site Godinne (Cliniques Universitaires UCL de Mont-Godinne), Godinne, Namur, Belgium
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5506
- Registration Number
- NCT05520138
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT05457257
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05422911
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.